Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease
Yizhong Wang, Xuefeng Gao, Xinyue Zhang, Fangfei Xiao, Hui Hu, Xiaolu Li, Fang Dong, Mingming Sun, Yongmei Xiao, Ting Ge, Dan Li, Guangjun Yu, Zhanju Liu, Ting Zhang
Abstract
, and higher fecal concentrations of amino acids, including L-aspartic acid, linoleic acid, and L-lactic acid at baseline. Our study suggests that the effects of IFX might be partially mediated by enriching bacteria taxa that producing SCFAs and BSH thereby inhibiting inflammation and restoring the BA metabolism. Some fecal bacteria and metabolites may be predictive of outcomes of IFX therapy for pediatric CD patients.
Topics & Concepts
InfliximabDiseaseCrohn's diseaseBiologyImmunologyIntensive care medicineInternal medicineMedicineTumor necrosis factor alphaInflammatory Bowel DiseaseMicroscopic ColitisGut microbiota and health